Company Overview of Ensemble Therapeutics Corporation
Ensemble Therapeutics Corporation develops and markets macrocycle therapeutics to the pharmaceutical industry. The company offers Ensemblins, a macrocycle drug to treat diseases by addressing drug targets, such as protein-protein interactions, phosphatases, and proteases; and Interleukin-17, a pro-inflammatory cytokine for the treatment of multiple inflammatory and autoimmune diseases, such as psoriasis, rheumatoid arthritis, Crohn’s, and intestinal bowel disease. The company’s products are used to treat cancer and autoimmune diseases, neurology, metabolic disease, infectious diseases, and diabetes. Ensemble Therapeutics Corporation has strategic alliance with Bristol-Myers Squibb; and Novar...
99 Erie Street
Cambridge, MA 02139-4535
Founded in 2002
Key Executives for Ensemble Therapeutics Corporation
Founding Scientist and Member of the Scientific Advisory Board
Senior Director of Finance & Administration
Senior Vice President of Biology
Senior Vice President of Corporate Development
Compensation as of Fiscal Year 2013.
Ensemble Therapeutics Corporation Key Developments
Ensemble Therapeutics and Novartis Announce Research and Development Collaboration Focused on Interleukin-17 Inhibitor Programme
Aug 7 13
Ensemble Therapeutics has announced a global strategic partnership with Novartis that will facilitate the development of Ensemble's lead investigational interleukin-17 (IL-17) cytokine inhibitor as well as a new initiative to discover novel small molecule candidates using Ensemble's proprietary drug discovery platform. Based on the agreement, Ensemble will receive an undisclosed upfront payment along with development and sales milestone payments. The firm will also be entitled to tiered royalties, if a successful candidate resulting from the collaboration is commercialized. The collaboration will further contribute to Novartis's inflammatory and autoimmune disorders portfolio, as the company can benefit from development of a first in class orally active small molecule IL-17 inhibitor that has been traditionally targeted with injectable protein therapeutics. According to Ensemble, the proprietary small molecule IL-17 inhibitor has comparable efficacy to existing biologic therapeutics targeting the cytokine in human clinical trials. Novartis will also have access to Ensemble's proprietary drug discovery chemistry-based technology that will try to develop and test various Ensemblins or synthetic macrocycles - small molecule candidates with protein surface binding properties. Macrocycles are difficult to synthesise on a large scale, but Ensemble has the capability of doing that in large numbers. Both companies stand to benefit, particularly in the large inflammatory and autoimmune market, if and when a candidate gains marketing approval.
Ensemble Therapeutics Presents Data Demonstrating Unique Properties of Synthetic Macrocycles
Feb 13 13
Ensemble Therapeutics announced that preclinical data showing the advantages of novel macrocyclic compounds against challenging drug targets, including its first-in-class, orally active small molecule antagonists of IL-17. The data that Ensemble's DNA-Programmed Chemistry discovery platform rapidly and successfully identifies novel, orally active small molecules against 'undruggable' targets that have historically proven intractable to traditional small molecule efforts, including protein-protein interaction targets like IL-17.
Ensemble Therapeutics Corporation Announces Positive Preclinical Oral Efficacy Data with First-In-Class Small Molecule Interleukin-17 (IL-17) Antagonists
Nov 12 12
Ensemble Therapeutics Corporation announced the positive preclinical oral efficacy data with its first-in-class small molecule Interleukin-17 (IL-17) antagonists. A presentation at the American College of Rheumatology (ACR) 2012 Annual Meeting, taking place November 9-14, 2012 in Washington, DC, revealed that the company's Ensemblins have strong oral activity as antagonists of IL-17, a pro-inflammatory cytokine implicated in multiple inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, Crohn's disease and inflammatory bowel disease. In a poster presentation entitled "Identification and Characterization of Synthetic Small Molecule Macrocycle Antagonists of Human IL17A", Dr. David J. Livingston, Ensemble SVP Biology, presented preclinical data on oral anti-IL-17A Ensemblins, including: High selectivity to the cytokine target: The anti-IL-17A Ensemblins bind to IL-17A and specifically inhibit IL-17A induction of cytokines and chemokines in cell assays. In addition, they demonstrate selectivity for IL-17 induced cellular responses compared to responses induced by other pro-inflammatory cytokines. Comparable anti-inflammatory efficacy to an anti-IL-17 antibody: The anti-IL-17A antagonist referred to as E-36041 was shown to be orally active in a murine collagen-induced arthritis (CIA) model, displaying similar protection from inflammation as an anti- mouse IL-17A antibody. Protection from arthritic joint degradation: E-36041 suppressed arthritis disease-induced changes in joints such as pannus formation and bone resorption and remodeling. Significant in Vivo Activity: The IL-17A inhibitors were active in vivo in murine models of acute inflammation when injected intraperitoneally (into the body cavity) or by oral gavage (feeding tube).
Similar Private Companies By Industry
Recent Private Companies Transactions
August 6, 2013